Literature DB >> 22608310

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.

Virginia M Klimek1, Emily K Dolezal, Michael T Tees, Sean M Devlin, Karen Stein, Alejandro Romero, Stephen D Nimer.   

Abstract

We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission+marrow CR+hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22608310     DOI： 10.1016/j.leukres.2012.04.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  9 in total

1.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

Review 2.  Therapy-related myeloid neoplasms - what have we learned so far?

Authors:  Mohammad Faizan Zahid; Aric Parnes; Bipin N Savani; Mark R Litzow; Shahrukh K Hashmi
Journal:  World J Stem Cells       Date:  2016-08-26       Impact factor: 5.326

3.  Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Authors:  A M Zeidan; N Al Ali; J Barnard; E Padron; J E Lancet; M A Sekeres; D P Steensma; A DeZern; G Roboz; E Jabbour; G Garcia-Manero; A List; R Komrokji
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

Review 4.  Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Authors:  Michael Heuser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.

Authors:  Giuseppe Leone; Emiliano Fabiani; Maria Teresa Voso
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

6.  Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Authors:  Alan H Shih; Stephen S Chung; Emily K Dolezal; Su-Jiang Zhang; Omar I Abdel-Wahab; Christopher Y Park; Stephen D Nimer; Ross L Levine; Virginia M Klimek
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

7.  Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature.

Authors:  Elisabetta Metafuni; Patrizia Chiusolo; Luca Laurenti; Federica Sorà; Sabrina Giammarco; Andrea Bacigalupo; Giuseppe Leone; Simona Sica
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

8.  5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair.

Authors:  Manuel Luís Orta; José Manuel Calderón-Montaño; Inmaculada Domínguez; Nuria Pastor; Estefanía Burgos-Morón; Miguel López-Lázaro; Felipe Cortés; Santiago Mateos; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2013-04-22       Impact factor: 16.971

Review 9.  Therapy-related myeloid neoplasms: clinical perspectives.

Authors:  Luana Fianchi; Marianna Criscuolo; Emiliano Fabiani; Giulia Falconi; Alessio Maria Edoardo Maraglino; Maria Teresa Voso; Livio Pagano
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.